











S76Interpreting Data on Transplant Selection and
Outcome in Adult Acute Lymphoblastic Leukemia (ALL)
Jacob M. RoweUntil 10 to 15 years ago allogeneic transplants were performed in acute lymphoblastic leukemkia (ALL)
mostly for advanced disease. They were rarely performed in first remission except for patients who were
positive for the Philadelphia chromosome. Over the past decade, allogeneic transplants are being increasingly
performed also for select patients in first remission, and the use of matched unrelated donors has vastly in-
creased the availability of the donor pool for ALL patients. The data for reduced-intensity conditioning (RIC)
transplants are at their infancy for ALL, but are likely to come into their own over the next decade, given the
vast potential of offering this also to older patients or those with comorbidities. Despite the plethora of data,
reports from various study groups differ in their enthusiasm for transplantation in many instances, and
published data are often contradictory. Much of the data may have inherent selection biases and their inter-
pretation may be confusing and difficult. The study conditions should be carefully described for physicians and
patients to be able to adequately interpret the data.
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Interpreting the outcome of transplantation in
adult ALL is hampered by conflicting results published
by various trial groups. All published studies are inher-
ently different. The differences may be because of
varying trial design and different eligibility criteria.
Moreover, even for similar trials the interpretation of
the results are affected by the sample size and maturity
of the data. Intention-to-treat analyses are intended to
overcome selection biases and remain the best way to
interpret data, but have their own significant limita-
tions that must be recognized, especially in the clinical
setting. As clinical decisions are based on published
data, which are often contradictory, it is incumbent
on the readers to ponder the intrinsic differences be-
tween the studies, allowing for ameasured understand-
ing of the fundamental message in each study. The
foregoing is intended to give some insight into com-
mon interpretive pitfalls resulting from publishedRambam Health Care Campus and Technion, Israel
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are equally applicable to transplantation for acute my-
elogenous leukemia (AML), the primary focus here is
on ALL, and thus, the issues reviewed here will mostly
be based on the ALL literature.
Because by far the largest prospective study of
transplantation in adult ALL was conducted by the
combined efforts of the Medical Research Council in
Great Britain and the Eastern Cooperative Oncology
Group in the United States (UKALL XII/ECOG
2993), much of the transplant data in this report will
be derived from this study.
Randomized Studies
Prospective randomized studies are the only way to
establish the value of transplantation in any form of
leukemia. However, several clinical indications for
transplant have come into their own based only on
phase II studies that were compared with established
historical data. Such was the case with the use of
allogeneic transplantation frommatched related or un-
related donors (MUD) for Philadelphia chromosome-
positive ALL patients, which in the preimatinib era
was the most widely accepted indication for an alloge-
neic transplantation, despite the absence of any
prospective randomized studies. Given the known
outcome with standard chemotherapy, this was
clearly appropriate. However, some of the transplant
data have come into their own without prospective
randomized information andmay not always be appro-
priate. The widespread use of reduced-intensity
Table 1. Donor versus No-Donor Analysis
Advantages Potential Pitfalls
 Prospective data  Underestimates toxicity
 Based on intention-to-treat analysis  May underestimate or overestimate efficacy
 Avoids time-to-treatment selection bias  Assignment to donor and no-donor groups may be at different time points
 Best available form of genetic randomization  Physician and patient biases impact who goes into donor group
 Depends on a reliable tissue typing facility
 Confounded if a significant proportion of patients do not receive assigned transplant
 Treatment in the no-donor group not always comparable across studies
 Does not provide information for patients who have selected themselves beyond initial induction
and intensification
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novel opportunity for a subset of population that could
not otherwise be transplanted, is nevertheless being
applied in lieu of standard myeloablative conditions,
in many instances without appropriate supportive pro-
spective studies. Similarly, the use of pediatric regi-
mens appear to have recently come into their own in
ALL for adolescents and young adults [1,2]. Several
publications have recently compared pediatric and
adult chemotherapy regimens for ALL in this age
group, apparently showing a superior outcome for
the young adults treated on typical pediatric
regimens. Such an approach has almost become
standard of care based only on retrospective studies.
There are also several issues that need to be
considered here. It is important to understand that
these regimens have not been studied in younger
adults; rather, they have been adopted [3,4]. All these
comparisons have been retrospective, and it is
important to recognize the difficulty in comparing
adolescents who are treated in adult settings with
those treated in pediatric units. Furthermore,
pediatric regimens are generally more intensive,
include far more asparaginase and probably reflect
a greater protocol discipline, especially about
timeliness of administration and adherence to those
schedules [5]. Thus, a degree of caution in the
widespread application of such regimens is also appro-
priate [3].
Intention-To-Treat: Donor versus No-Donor
Analysis
Intention-to-treat analyses of patients with donors
versus no donors have become the gold standard for
presentation of randomized data in allogeneic trans-
plant studies. In theory, they avoid the obvious time-
to-treatment selection bias, including only patients
who are eligible for allogeneic transplantation in the
donor arm and including all others in the no-donor
arm, irrespective of whether patients actually receive
their randomized or assigned therapy. A donor versus
no-donor analysis represents the best available meth-
odology for a genetic randomization, recognizing
that a true randomized transplant study among patients
with a sibling or alternative donor has never been
performed and, in all probability, will never be done.However, there are significant limitations even among
donor versus no-donor analyses that need to be consid-
ered (Table 1). First, intention-to-treat analyses in
transplant studies underestimate the toxicity of the
procedure, because the donor arm is diluted by the
number of patients who do not receive the transplant.
The International MRC UKALL XII/ECOG 2993
study carefully published the nonrelapse mortality
(NRM) associated with patients who actually under-
went an allogeneic transplant [6] (Figure 1). For
high-risk patients, a 2-year NRM of 36% among
patients over 35 years may thus seem higher than in
other publications, but this needs to be carefully as-
sessed when comparing such data with other publica-
tions where the NRM is reported for a shorter
period, such as 1 year, and often is determined
by intention-to-treat rather than the true risk of mor-
tality. Furthermore, mortality is often expressed as
transplant-related mortality (TRM) which, depending
on interpretation, may be significantly less than NRM,
which includes mortality from all causes. Similarly,
intention-to-treat analyses may overestimate or under-
estimate the true efficacy of transplant depending on
whether this was better or worse than the control
arm. Finally, when assessing the true toxicity of the
transplant procedure careful attention needs to be
paid to the NRM in the control arm, which allows for
a more realistic understanding of the incremental risk
ofmortality from allogeneic transplantation (Figure 1).
Second, it is crucial that assignment to the donor
and no-donor groups be performed at as close a time
period as possible. Thus, a patient who has no siblings
could theoretically be assigned to the no-donor group
at diagnosis, introducing a bias in favor of the donor
group. Similarly, it may take longer to complete a do-
nor search among families where siblings may be scat-
tered instead of having a single sibling in 1 place. If
a patient with a sibling were to relapse early or die in
remission, before tissue typing was complete, they
will be excluded from the analysis on the basis that
the presence or absence of a donor has not been estab-
lished, leading to a differential exclusion of early events
in patients who have been found to have a donor [7,8].
Thus, it is crucial in publications to clearly specify how
and at what time point patients were assigned into the
donor or no-donor group. A practical way of doing this
Figure 1. NRM for patients who underwent an allogeneic transplant. Data not by intention-to-treat analysis. Reproduced with permission from
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High Risk ALL in CR1
Figure 2. Meta-analysis of high-risk ALL in 7 studies showing an overall
benefit for the donor group. Reproduced with permission from Yanada
et al. [11].
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is not always the case.
Third, in practice, physician and patient biases
may impact on who goes into the donor or no-donor
group, as a true search for a donor often depends on
how hard one tries. This is especially so in case of a dis-
tant sibling or in case where the initial tissue typing of
the patient was unsuccessful because of a low number
of cells. Fourth, it goes without saying that a donor
versus no-donor analysis is only meaningful if each
participating center has a reliable tissue typing facility
available. Having the availability of a rapid central re-
view of tissue typing, as is done in some countries,
helps to overcome such potential bias.
Fifth, any intention-to-treat analysis can only be
reliably assessed if patients actually receive the treat-
ment specified in their genetic assignment/randomiza-
tion. The problemwith all transplant studies is that not
all patients in the donor arm will receive an allogeneic
transplant, often for nonprotocol reasons related to pa-
tient or physician biases. Sophisticated statistical cor-
rections that may exist can never adequately account
for this if it occurs in a very large number. Studies of au-
tologous transplants are notorious for this with any-
where between 40% and 50% of patients randomized
to such a transplant not receiving the procedure, mak-
ing interpretation by a intention-to-treat analysis im-
possible, despite any corrections [9,10]. For ALL, in
a genetic randomization to an allogeneic transplant
the proportion of patients actually undergoing the
transplant is closer to 70%-80% in most published
studies, still leaving a major compliance issue that
will lead to a dilution of the transplant effect.
Therefore, in any donor versus no-donor analysis it is
crucial to specify the number of patients in the donor
arm who actually received the transplant.Sixth, comparisons of outcome of an allogeneic
transplant in the donor group are only meaningful if
the no-donor group is treated in a fairly consistent or
reproducible fashion. Eligibility criteria and therapeu-
tic regimens are variable, leading to completely differ-
ent results in the no-donor group, which impacts on
the ultimate outcome. As an example, the international
MRC/ECOG study reported that the benefit of a do-
nor was most significant in the standard risk patients.
Among high-risk patients, although there was an im-
pressive reduction in relapse rate because of the potent
graft-versus-leukemia effect, the NRM abrogated this
overall survival (OS) benefit, such that a significant ad-
vantage to a sibling allogeneic transplant in the donor
group could not be demonstrated [6]. Although mostly
driven by transplants for patients over 35, this finding
was in contrast to previous published data, confirmed
Figure 3. Donor versus no-donor analysis for high-risk patients in the
LALA 94 study.Reproduced with permission from Thomas et al. [12].
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controversial (Figure 2). However, the largest previ-
ously published data on transplants for ALL in first re-
mission and the 1 conducted most similar to the
ECOG/MRC study, was the French LALA-94 trial,
published in 2004 [12]. This study has widely chal-
lenged the International ALL study because of the
highly significant difference between donor and no-
donor arms among high-risk patients. However, as
can be seen in Figure 3, the favorable outcome for
high-risk patients in the LALA-94 trial is not because
of a particularly superior outcome in the donor group,
but rather due to a surprisingly low 18% disease-free
survival (DFS) rate in the no-donor arm, which makes
comparisons with the ECOG/MRC study meaning-
less. In theory, differences in the performance of allo-
geneic transplants, such as varying the conditioning
regimen, could affect comparisons even in the donor
group, but the available data suggest that such differ-
ences have minimal impact at most.Figure 4. Comparison of OS for autologous transplant versus chemotherapy
analysis, showing the superiority of chemotherapy. Reproduced with permissio
actually received.Finally, although recognizing that the intention-to-
treat analysis is the best method for assessing the true
impact of a given treatment on the disease, it often lacks
relevant information for an individual patient at a point
beyond diagnosis. Thus, a patient who has successfully
undergone induction therapy, has achieved a complete
remission (CR),with orwithout significant toxicity, and
is beyond several courses of intensification, typically
consults with a physician for themost appropriate ther-
apy at that juncture. Such a patient cannot depend upon
data from intention-to-treat analysis to provide a cor-
rect assessment of a true efficacy and toxicity for that
time point [13]. This is a generic issue affecting all pro-
spective studies of AML and ALL. As an example, con-
sider the data from the MRC/ECOG study regarding
randomization between chemotherapy and autologous
transplants for patients who do not have a donor. The
data were appropriately analyzed by an intention-
to-treat analysis. Autologous transplant appeared to
be inferior to chemotherapy [6] (Figure 4A), in contrast
to considerable historic data that suggested that autol-
ogous transplant would be at least as good as chemo-
therapy [12,14,15]. However, in this trial, as in other
studies of autologous transplant, many patients did
not undergo their randomized treatment and so,
interpretation of these data is difficult and a physician
is in a quandary when consulting a patient. The data
for patients who have selected themselves to the point
of having survived all prior therapies and now being
fit to undergo a transplant suggest that such
a procedure may yet be a preferred option, or at least
not inferior to chemotherapy (Figure 4B). The out-
come of transplants other than by intention-to-treat
analysis has almost never been reported in the litera-
ture. There is a perhaps mistaken perception that phy-
sicians and patients may misinterpret such information
and fail to understand the importance of avoiding biasesin the MRCUKALLXII/ECOG 2993 study. (A) Data by intention-to-treat
n from Goldstone et al. [6]. (B) Data from the same study by treatment
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though recognizing the overriding unbiased impor-
tance of a donor versus no-donor analysis [16], also
presenting the outcome data of patients who actually
undergo the procedure is clearly useful, provided these
have been appropriately interpreted.Definition of Complete Remission and Risk
Status
Comparisons of the transplant outcome in first re-
missiondependonanaccurate assessmentofpatients re-
ported to enter CR. Although age is clearly stated, there
are subtle and not so subtle differences between studies
that hamper the interpretation of the data. Atlhough the
International MRC/ECOG study allowed for all the
patients to enter the study, irrespective of their perfor-
mance status, cardiac, pulmonary, renal, or hepatic
functions, other studies have limited their eligibility cri-
teria to patients who have a good performance status
[17], adequate renal or hepatic function [18], or good
cardiac or pulmonary function [19]. Still, more recent
studies have removed patients who are not in remission
after the initial 4-week phase I of induction, although in
most studies patients are considered in CR even if they
entered remission after 2 phases of induction.
Another important variable between studies relates
to the definition of the risk status. This is clearly amov-
ing target as a better understanding of what constitutes
high risk, based on cytogenetic or molecular findings
at diagnosis, and the determination of minimal resid-
ual disease (MRD) after induction and intensification,
all need to be very clearly specified for a reliable
comparison to be made between the studies.Figure 5. Survival from first relapse in 609 patients in the MRCUKALLXII/ECO
(B) Survival from allogeneic sibling transplant in CR2. Reproduced with permis
ALL. Patients who were transplanted at CR2 or in subsequent remission. RepAdequate Sample Size
There are never enough patients in any study to
provide reliable data for every conceivable subgroup.
This has been a pitfall of major studies in AML that
were initially designed to compare transplant with
chemotherapy and were sized appropriately for this.
Subsequently, as the importance of cytogenetics and
molecular determinants was reported, it was clear that
considering AML as a whole was meaningless without
subdividing this into the appropriate cytogenetic risk
groups, at which point the samples were too small,
leading to confusing and contradictory published results
[20,21].Clearly, the sameapplies for acute lymphoblastic
leukemia (ALL), given the increasing understanding of
prognostic importance of cytogenetics and molecular
determinants [22,23]. Nevertheless, it is crucial for
the studies to be as adequately sized as is possible,
recognizing that this will never be perfect. This
consideration was 1 of the driving forces that kept the
very large International MRC/ECOG study alive for
13 years, despite considerable pressures, in an attempt
to provide a sample size that would enable confident
interpretation of the data. No statistical methodology
can adequately overcome the inherent limitations of
small studies.Outcome After Relapse
One of the most important issues relates to the
timing of transplant. Published data indicating
a successful outcome after relapse mostly by way of
transplantation at that point [24,25] (Figure 5B) have
confused many physicians and patients. Sometimes,
patients are presented with such information regardingG 2993 study. (A) Reproducedwith permission from Fielding et al. [26].
sion from Doney et al. [24]. (C) CIBMTR data over the past decade for
roduced with permission from Pasquini et al. [25].
Figure 6. OS for Ph-negative patients treated on the MRC UKALLXII/ECOG 2993 study. (A) Data for high-risk patients as published in 2008 upon
completion of study. Reproducedwith permission fromGoldstone et al. [6]. (B) Data for high-risk patients from the same study presented 5 years earlier,
with a shorter follow-up and smaller numbers. (C) Data for standard-risk patients as published in 2008 upon completion of study. Reproduced with
permission from Goldstone et al. [6]. (D) Data for standard-risk patients from the same study represented 5 years earlier, with a shorter follow-up
and smaller numbers.
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event of relapse. Given the high NRM, such informa-
tion may sway patients away from transplant in CR1.
Such reports are highly selective and relate only to
patients who have survived a relapse and are fit enough
to receive a transplant in second remission. The
predictive overall survival for ALL patients who have
relapsed is exceedingly poor; no more than around
7%. Figure 5A represents the data from 609 adults
who relapsed on theMRC/ECOGstudy.This is a non-
select report that includes all patients, irrespective of
the therapy that was given. Even among 116 patients
who had a CR1 of .2 years the long-term survival
from relapse is only 7% [26]. Similarly, the 429 pa-
tients who received chemotherapy in CR1 and were
theoretical candidates for a transplant at relapse also
had a 7% long-term survival [26]. Thus, despite the
high procedural mortality, such select data from trans-
plantation in CR2 cannot be used at diagnosis to per-
suade patients to delay a transplant until relapse, in
those instances where the survival benefit of transplant
in CR1 appears to be clearly established in a prospec-
tive study.Early Publication of Data
The literature is full of examples where initial in-
terim data are presented only to be reversed when
the study has been completed and the data are mature.
Although early presentation of data may be important
to guide investigators in the design of future studies,
such data need to be very cautiously and circumspectlyinterpreted. Figure 6 is an excellent demonstration of
how an early presentation of data, even with large
numbers, can be misleading. As previously discussed,
in the MRC/ECOG study, when all the data were ma-
ture, a significant benefit could not be demonstrated
for high-risk patients among the donor group
(Figure 6A). However, when the data were presented
5 years earlier with a shorter median follow-up and
only about half of the patients accrued, there appeared
a significant benefit for the high-risk cohort
(Figure 6B). Similarly, the significant benefit for
patients at standard risk reported when the study had
matured (Figure 6C) could not be as convincingly
demonstrated when the data were prematurely re-
ported 5 years earlier (Figure 6D). Another example
from the same study relates to patients who were
Philadelphia chromosome positive. The data pre-
sented at the annual meeting of the American Society
of Hematology in 2007 surprised the international
community, failing to demonstrate a superior outcome
for ALL patients with imatinib (Figure 7). However, 3
years later, a subsequent mature presentation, at the
samemeeting in 2010, reported an unequivocal benefit
for patients receiving imatinib, in line with a multitude
of other published data [27].Alternative Donor Transplants
Transplants from alternative donors, especially
matched unrelated donors (MUD), are increasingly
used, also in ALL. Over the past few years several
publications have clearly demonstrated the feasibility
Figure 7. Ph-positive patients treated on the MRC UKALLXII/ECOG
2993 study, comparing imatinib and preimatinib era. Oral presentation
at the 2007 annual meeting of the American Society of Hematology [31].
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reports have gone so far as to indicate the
comparable outcome after related or unrelated stem
cell transplantation for ALL [29,30]. None of these
comparisons are based on intention-to-treat analyses
and therefore needs to be interpreted appropriately
as they report on patients who actually received a re-
lated or unrelated donor transplant, but do not take
into account the inherent selection that goes into
assigning a patient to a MUD transplant. The patient
eligibility criteria for such a procedure may be more
restrictive than for a sibling transplant. Despite the
widespread perception of a similar outcome, it is com-
mon practice for a discrepant approach in the institu-
tional policy in many major transplant centers. For
example, although a 32-year-old patient at standard
risk may be unhesitatingly referred for a related sibling
transplant, there is far greater hesitation to send such
a patient to a MUD transplant, in the absence of any
adverse risk factors.CONCLUSIONS
Great strides have been made over the past decades
in defining the optimal role for allogeneic and autolo-
gous transplantation in adult patients with ALL.
Vastly increasing the donor pool through the use of al-
ternative donors and, in the future, through the use of
reduced intensity transplantation have resulted in far
more allogeneic transplants being performed provid-
ing a great deal more data. Nevertheless, ALL in adults
remains an uncommon disorder, and reliable data can
only come from well-conducted large prospective
studies that need to be achieved through a collaborative
effort among groups and across continents. In the
meantime, great attention needs to be given to the
appropriate methodologies for each study to fully un-
derstand the importance of the data provided as well as
the limitations. The horizons of transplantation are
shifting rapidly, as for patients with the Philadelphiachromosome treated with tyrosine kinase inhibitors
and in the future through the use of reduced intensity
conditioning. Using data on MRD to guide the opti-
mal indications for transplant is now being actively
studied and may significantly impact in the future on
the indications for transplantation.ACKNOWLEDGMENTS
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